Abstract:Background: Oncolytic virotherapy is an upcoming treatment option for many tumor entities. But so far, a first oncolytic virus only was approved for advanced stages of malignant melanomas. Neuroendocrine tumors (NETs) constitute a heterogenous group of tumors arising from the neuroendocrine system at diverse anatomic sites. Due to often slow growth rates and (in most cases) endocrine non-functionality, NETs are often detected only in a progressed metastatic situation, where therapy options are still severely limited. So far, immunotherapies and especially immunovirotherapies are not established as novel treatment modalities for NETs. Methods: In this immunovirotherapy study, pancreatic NET (BON-1, QGP-1), lung NET (H727, UMC-11), as well as neuroendocrine carcinoma (NEC) cell lines (HROC-57, NEC-DUE1) were employed. The well characterized genetically engineered vaccinia virus GLV-1 h68, which has already been investigated in various clinical trials, was chosen as virotherapeutical treatment modality. Results: Profound oncolytic efficiencies were found for NET/NEC tumor cells. Besides, NET/NEC tumor cell bound expression of GLV-1 h68-encoded marker genes was observed also. Furthermore, a highly efficient production of viral progenies was detected by sequential virus quantifications. Moreover, the mTOR inhibitor everolimus, licensed for treatment of metastatic NETs, was not found to interfere with GLV-1 h68 replication, making a combinatorial treatment of both feasible. Conclusions: In summary, the oncolytic vaccinia virus GLV-1 h68 was found to exhibit promising antitumoral activities, replication capacities and a potential for future combinatorial approaches in cell lines originating from neuroendocrine neoplasms. Based on these preliminary findings, virotherapeutic effects now have to be further evaluated in animal models for treatment of Neuroendocrine neoplasms (NENs).

Progress of Oncolytic Virotherapy for Neuroblastoma

Research therapeutic advances of oncolytic virus for neuroblastoma

Clinical and pathological analysis of the olfactory neuroblastoma

Oncolytic virotherapy augments self-maintaining natural killer cell line cytotoxicity against neuroblastoma

Oncolytic virus therapy for malignant gliomas: entering the new era

Oncolytic virotherapies for pediatric tumors

Nanotechnology-Based Diagnostic and Therapeutic Strategies for Neuroblastoma

Efficacy and Safety of Oncolytic Virus Immunotherapy in Advanced Malignancies: A Systematic Review of 161 Clinical Studies

Clinical advances in oncolytic virotherapy for pediatric brain tumors

The emerging field of viroimmunotherapy for pediatric brain tumors

Engineered Measles Virus Edmonston Strain Used As a Novel Oncolytic Viral System Against Human Neuroblastoma Through a CD46 and Nectin 4-Independent Pathway

Research frontiers and reflections on neuroblastoma

Neuroblastoma: clinical and biological approach to risk stratification and treatment

Pathogenesis, Biomarkers and Therapeutic Targets

Extracellular vesicles in neuroblastoma: role in progression, resistance to therapy and diagnostics

Clinical Advances and Future Directions of Oncolytic Virotherapy for Head and Neck Cancer

Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions

Oncolytic vaccinia virus GLV-1h68 exhibits profound antitumoral activities in cell lines originating from neuroendocrine neoplasms

A viral attack on brain tumors: the potential of oncolytic virus therapy

Research advances of MYCN and ALK gene-related targeted drugs in the treatment of neuroblastoma

High-Risk Neuroblastoma Challenges and Opportunities for Antibody-Based Cellular Immunotherapy